KMDA250117C5000
- 1.65
- 0.000.00%
Kamada Newsroom
Kamada Gets $25 Million Contract to Supply Kamrab, Varizig in Latin America; Shares Rise
Express News | Kamada Announces a $25 Million 3-Year Contract for Supply of Kamrab® and Varizig® in Latin America
Stifel Maintains Kamada(KMDA.US) With Buy Rating
Stifel Nicolaus Reaffirms Their Buy Rating on Kamada (KMDA)
Kamada Up Nearly 14%, on Track for Highest Close Since February 2021 -- Data Talk
Kamada Shares Rise 16% on Earnings Outlook, Trial Progress
Kamada Shares Are Trading Higher After the Company Issued FY25 Guidance Above Estimates.
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations
Kamada: Based on Change, Co to Reduce Sample Size to 180 Patients From 220 >KMDA.TA.TV
Kamada: FDA Agrees With Error Control Rate Change for Phase 3 Trial for Alpha-1 Antitrypsin >KMDA.TA.TV
Kamada Sees 2024 Year-End Cash of $78M >KMDA.TA.TV
Kamada Reaffirms 2024 Targets, Unveils 2025 Guidances, Revenue Of $178M-$182M Vs. $171.18M Est. And Adj.EBITDA Of $38M-$42M
Express News | Kamada Ltd: Outlook FY25 Rev $178 Mln - $182 Mln
US Manufacturing Index Rises To 43, Highest Since 2020
Kamada Analyst Ratings
H.C. Wainwright Maintains Kamada(KMDA.US) With Buy Rating, Maintains Target Price $11
Kamada's Promising Growth Potential Backed by Phase 3 InnovAATe Trial and Strong Market Position Justifies Buy Rating
Stifel Maintains Kamada(KMDA.US) With Buy Rating, Raises Target Price to $20
Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript Summary
Kamada's Strong Growth and Strategic Expansion in 2024